Publications by authors named "Laura Ojeda-Marquez"
Article Synopsis
- Lung adenocarcinoma is a type of lung cancer that often has mutations in a gene called EGFR, which doctors can target with special medicines.
- Some patients do not respond well to these medicines, so researchers are looking for better ways to predict who will benefit from the treatment.
- The study found that a protein called FGFR4 works with EGFR, making tumors more resistant to treatments, but combining both types of inhibitors could be a good strategy for patients with high FGFR4 levels.
Introduction: There is substantial evidence for the oncogenic effects of fibroblast growth factor receptor 1 (FGFR1) in many types of cancer, including lung cancer, but the role of this receptor has not been addressed specifically in lung adenocarcinoma.
Methods: We performed FGFR1 and EGFR overexpression and co-overexpression assays in adenocarcinoma and in inmortalized lung cell lines, and we also carried out surrogate and interaction assays. We performed monotherapy and combination EGFR/FGFR inhibitor sensitivity assays in vitro and in vivo in cell line- and patient-derived xenografts.
The FGFR4-388Arg variant has been related to poor prognosis in several types of cancer, including lung cancer. The mechanism underlying this association has not been addressed in detail in patients with this pathology. Here, we report that this FGFR4 variant induces MAPK and STAT3 activation and causes pro-oncogenic effects in NSCLC in vitro and in vivo.
View Article and Find Full Text PDF